{"id":"https://openalex.org/W68218898","doi":"https://doi.org/10.1182/blood.v122.21.4853.4853","title":"Rational Development Of Lipegfilgrastim, a Novel Long-Acting Granulocyte Colony-Stimulating Factor, Using Glycopegylation Technology","display_name":"Rational Development Of Lipegfilgrastim, a Novel Long-Acting Granulocyte Colony-Stimulating Factor, Using Glycopegylation Technology","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W68218898","doi":"https://doi.org/10.1182/blood.v122.21.4853.4853","mag":"68218898"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.4853.4853","doi":"https://doi.org/10.1182/blood.v122.21.4853.4853","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.4853.4853","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027918851","display_name":"Felix Mahlert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Felix Mahlert","raw_affiliation_strings":["Merckle Biotec GmbH, Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merckle Biotec GmbH, Ulm, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101474683","display_name":"Karsten Schmidt","orcid":"https://orcid.org/0000-0002-8392-5943","observed_orcids":["https://orcid.org/0000-0002-8392-5943"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Karsten Schmidt","raw_affiliation_strings":["BioGeneriX GmbH, Ulm, Germany,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioGeneriX GmbH, Ulm, Germany,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056801830","display_name":"Hermann Allgaier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Hermann Allgaier","raw_affiliation_strings":["Merckle Biotec GmbH, Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merckle Biotec GmbH, Ulm, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071017377","display_name":"Patrick Liu","orcid":"https://orcid.org/0000-0002-2751-0129","observed_orcids":["https://orcid.org/0000-0002-2751-0129"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Patrick Liu","raw_affiliation_strings":["Teva Pharmaceuticals, Inc., Rockville, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Teva Pharmaceuticals, Inc., Rockville, MD, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105936966","display_name":"Udo M\u00fcller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139694","display_name":"Teva Pharmaceuticals (Germany)","ror":"https://ror.org/03xa4xh46","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210109720","https://openalex.org/I4210139694"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Udo M\u00fcller","raw_affiliation_strings":["Teva Pharmaceuticals, Inc., Ulm, Germany,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Teva Pharmaceuticals, Inc., Ulm, Germany,","institution_ids":["https://openalex.org/I4210139694"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102096944","display_name":"Wenyan David Shen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139373","display_name":"Teva Pharmaceuticals (United States)","ror":"https://ror.org/03etg4523","country_code":"US","type":"company","lineage":["https://openalex.org/I4210109720","https://openalex.org/I4210139373"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Wenyan David Shen","raw_affiliation_strings":["Teva Pharmaceuticals, Inc., West Chester, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Teva Pharmaceuticals, Inc., West Chester, PA, USA","institution_ids":["https://openalex.org/I4210139373"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5027918851","https://openalex.org/A5056801830","https://openalex.org/A5071017377","https://openalex.org/A5101474683","https://openalex.org/A5102096944","https://openalex.org/A5105936966"],"corresponding_institution_ids":["https://openalex.org/I4210139373","https://openalex.org/I4210139694"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.9536,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":{"value":0.73103496,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"122","issue":"21","first_page":"4853","last_page":"4853"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.9437999725341797,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.9437999725341797,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":0.01730000041425228,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00800000037997961,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lipegfilgrastim","display_name":"lipegfilgrastim","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pegfilgrastim","display_name":"pegfilgrastim","score":0.9079999923706055},{"id":"https://openalex.org/keywords/granulocyte-colony-stimulating-factor","display_name":"granulocyte colony-stimulating factor","score":0.9440000057220459},{"id":"https://openalex.org/keywords/pegylation","display_name":"PEGylation","score":0.800000011920929},{"id":"https://openalex.org/keywords/o-glycosylation","display_name":"O-glycosylation","score":0.8029999732971191},{"id":"https://openalex.org/keywords/sialic-acid","display_name":"sialic acid","score":0.6420000195503235},{"id":"https://openalex.org/keywords/n-acetylgalactosaminyltransferase","display_name":"N-acetylgalactosaminyltransferase","score":0.8799999952316284},{"id":"https://openalex.org/keywords/sialyltransferase","display_name":"sialyltransferase","score":0.9610000252723694},{"id":"https://openalex.org/keywords/chemotherapy-induced-neutropenia","display_name":"chemotherapy-induced neutropenia","score":0.7519999742507935},{"id":"https://openalex.org/keywords/protein-physicochemical-properties","display_name":"protein physicochemical properties","score":0.46000000834465027}],"concepts":[{"id":"https://openalex.org/C2778658803","wikidata":"https://www.wikidata.org/wiki/Q1592932","display_name":"Pegfilgrastim","level":5,"score":0.8771637678146362},{"id":"https://openalex.org/C2779149719","wikidata":"https://www.wikidata.org/wiki/Q682252","display_name":"PEGylation","level":3,"score":0.8534809947013855},{"id":"https://openalex.org/C2779171977","wikidata":"https://www.wikidata.org/wiki/Q3151081","display_name":"Filgrastim","level":4,"score":0.8384830355644226},{"id":"https://openalex.org/C2777767877","wikidata":"https://www.wikidata.org/wiki/Q419327","display_name":"Granulocyte colony-stimulating factor","level":3,"score":0.5328792929649353},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5312217473983765},{"id":"https://openalex.org/C54400483","wikidata":"https://www.wikidata.org/wiki/Q1793202","display_name":"PEG ratio","level":2,"score":0.4788251221179962},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4471207857131958},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.44492509961128235},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.4442819654941559},{"id":"https://openalex.org/C2777313579","wikidata":"https://www.wikidata.org/wiki/Q898365","display_name":"Glycosylation","level":2,"score":0.4250425398349762},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.39333269000053406},{"id":"https://openalex.org/C2776964284","wikidata":"https://www.wikidata.org/wiki/Q410083","display_name":"Polyethylene glycol","level":2,"score":0.38761019706726074},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.31161177158355713},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21129456162452698},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.4853.4853","doi":"https://doi.org/10.1182/blood.v122.21.4853.4853","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.4853.4853","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2525305701","https://openalex.org/W389520367","https://openalex.org/W2567660029","https://openalex.org/W2014576677","https://openalex.org/W2325803514","https://openalex.org/W2766537721","https://openalex.org/W2338082039","https://openalex.org/W3016331353","https://openalex.org/W2287419145","https://openalex.org/W3101857764"],"abstract_inverted_index":{"Abstract":[0,397,442,493],"Introduction":[1],"Recombinant":[2],"human":[3,31],"granulocyte":[4],"colony-stimulating":[5],"factors":[6],"(G-CSFs)":[7],"are":[8],"indicated":[9],"for":[10,99,205,515],"the":[11,55,59,63,76,100,130,143,158,184,197,202,212,234,264,268,280,286,291,295,332,354,377,479,505,516],"prevention":[12,101,517],"of":[13,30,38,43,65,72,102,110,137,146,153,171,181,241,252,294,326,336,349,356,453,481,507,518],"chemotherapy-induced":[14,103,519],"febrile":[15],"neutropenia":[16,483],"in":[17,188,299,339,359,365,415,478,484],"patients":[18,485],"receiving":[19],"myelosuppressive":[20],"chemotherapy.":[21],"Filgrastim":[22],"is":[23,49,74,96,313,345,497,524],"a":[24,35,50,69,119,174,253,283,300,314,327,350,366,447,464,508],"175-amino-acid,":[25],"short-acting,":[26],"recombinant":[27,221],"methionyl":[28],"form":[29],"G-CSF":[32,125,198,222,296,337,357],"(r-metHuG-CSF)":[33],"with":[34,260,282,303,369,405,433,451,486],"molecular":[36],"weight":[37,320],"\u223c19":[39],"kDa.":[40],"The":[41,105,150,308,521],"addition":[42,170],"polyethylene":[44],"glycol":[45],"(PEG)":[46],"via":[47],"PEGylation":[48,159,363],"well-established":[51],"technology":[52,163],"that":[53,167,209,452,503],"improves":[54],"physicochemical":[56,135],"profile,":[57],"enhances":[58],"solubility,":[60],"and":[61,108,112,134,139,141,207,362,381,391,408,427,500,527,538,541,543],"prolongs":[62],"half-life":[64,449],"therapeutic":[66,301,512],"proteins.":[67],"Pegfilgrastim,":[68],"PEGylated":[70,371],"version":[71],"filgrastim,":[73],"currently":[75],"only":[77,86,290],"available":[78],"long-acting":[79,93,124,550],"G-CSF,":[80,94],"requiring":[81,373],"fixed-dose":[82],"subcutaneous":[83],"(SC)":[84],"administration":[85,537],"once":[87],"per":[88],"chemotherapy":[89],"cycle.":[90],"A":[91,161,271],"new":[92],"lipegfilgrastim,":[95,111,312,514],"under":[97],"investigation":[98],"neutropenia.":[104,520],"rational":[106,151],"design":[107,152],"development":[109],"its":[113],"novel":[114,162],"manufacturing":[115,378,522],"process,":[116],"may":[117],"provide":[118,403],"valuable":[120],"fixed-dose,":[121],"once-per-cycle,":[122],"alternative":[123,549],"option.":[126],"This":[127],"analysis":[128],"compares":[129],"design,":[131],"protein":[132,199,217,262],"chemistry,":[133],"properties":[136],"lipegfilgrastim":[138,154,390,404,418,470],"pegfilgrastim,":[140],"evaluates":[142],"clinical":[144],"implications":[145],"their":[147],"differences.":[148],"Methods":[149],"focused":[155],"on":[156,216],"refining":[157],"process.":[160,379],"platform":[164],"was":[165,193,230,247,276,471],"developed":[166],"enabled":[168],"selective":[169],"PEG":[172,330,352],"to":[173,183,195,200,232,279,331,353,402,473,476,545],"previously":[175],"enzymatically":[176,277],"attached":[177],"glycan":[178],"moiety":[179],"instead":[180],"directly":[182],"amino":[185],"acid":[186,274],"(as":[187],"standard":[189],"PEGylation).":[190],"Sequon":[191],"scanning":[192],"used":[194],"scan":[196],"identify":[201],"best":[203],"sites":[204],"glycosylation":[206],"glycoPEGylation":[208,287,310,400],"would":[210],"have":[211,384],"least":[213],"predicted":[214],"effect":[215],"biologic":[218],"activity.":[219],"In":[220,342,411,463],"derived":[223],"from":[224],"Escherichia":[225],"coli":[226],"(E.":[227],"coli),":[228],"this":[229,245],"determined":[231],"be":[233,474,546],"single,":[235],"natural,":[236],"non-utilized":[237],"O-glycosylation":[238,292,334],"site.":[239,270],"Addition":[240],"an":[242,304,498,531,547],"O-glycan":[243,281],"at":[244,263],"site":[246,293,335],"achieved":[248],"by":[249,324,347],"enzymatic":[250],"activity":[251],"selective,":[254],"truncated":[255],"N-acetylgalactosaminyltransferase":[256],"isoform":[257],"2":[258],"fused":[259],"maltose-binding":[261],"threonine":[265],"residue":[266],"within":[267],"chosen":[269],"20-kDa":[272,329,351],"PEG-sialic":[273],"derivative":[275],"transferred":[278],"sialyltransferase.":[284],"Thus,":[285],"process":[288,502,523],"modified":[289],"protein,":[297,513],"resulting":[298],"product":[302,368],"extended":[305,532],"half-life.":[306],"Results":[307],"resultant":[309],"product,":[311],"long-acting,":[315],"site-specific":[316],"glycoPEGylated":[317],"r-metHuG-CSF":[318],"(molecular":[319],"\u223c38":[321],"kDa)":[322],"produced":[323,346],"conjugation":[325,348],"single":[328],"natural":[333],"expressed":[338,358],"E.":[340,360],"coli.":[341],"comparison,":[343],"pegfilgrastim":[344,392,434,454,477],"N-terminal":[355],"coli,":[361],"results":[364],"heterogeneous":[367],"multiple":[370],"isoforms":[372],"further":[374],"purification":[375],"during":[376],"Potency":[380],"receptor-binding":[382],"studies":[383,414],"shown":[385,472],"no":[386],"apparent":[387],"difference":[388],"between":[389],"(Scheckermann":[393],"C,":[394],"2013,":[395],"EHA,":[396,492],"P1024).":[398],"However,":[399],"appears":[401,544],"different":[406],"pharmacokinetic":[407],"pharmacodynamic":[409],"profiles.":[410],"phase":[412,467],"I":[413],"healthy":[416],"volunteers,":[417],"6":[419,435],"mg":[420,436],"SC":[421,437,536],"had":[422,446],"\u223c64%":[423],"greater":[424],"cumulative":[425],"exposure":[426,431,542],"\u223c36%":[428],"higher":[429],"peak":[430],"compared":[432,450],"(Kohler":[438],"E,":[439],"2012,":[440,491],"MASCC/ISOO,":[441],"A-445-0013-00997).":[443],"Lipegfilgrastim":[444,529],"also":[445],"longer":[448],"(geometric":[455],"means,":[456],"32.4":[457],"hours":[458],"vs":[459],"27.2":[460],"hours,":[461],"respectively).":[462],"double-blind,":[465],"randomized,":[466],"III":[468],"trial,":[469],"noninferior":[475],"duration":[480],"severe":[482],"breast":[487],"cancer":[488],"(Udo":[489],"M,":[490],"1375).":[494],"Conclusions":[495],"GlycoPEGylation":[496],"advanced":[499],"efficient":[501],"permits":[504],"manufacture":[506],"novel,":[509],"customized,":[510],"homogenous":[511],"simple,":[525],"controllable,":[526],"scalable.":[528],"has":[530],"half-life,":[533],"permitting":[534],"once-per-cycle":[535],"improved":[539],"bioavailability":[540],"effective":[548],"G-CSF.":[551],"Disclosures:":[552],"Mahlert:":[553],"Merckle":[554],"Biotec":[555],"GmbH":[556,563],"(Teva":[557,564,573],"Pharmaceuticals,":[558,574,579,583,587],"Inc.":[559,566,575],"Company):":[560],"Employment.":[561,568,577,581,585,589],"Schmidt:BioGeneriX":[562],"Pharmaceuticals":[565],"company):":[567,576],"Allgaier:Merckle":[569],"GmbH,":[570],"Ulm,":[571],"Germany":[572],"Liu:Teva":[578],"Inc:":[580,584,588],"M\u00fcller:Teva":[582],"Shen:Teva":[586]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}